Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma
Yujie Huang, … , David Lyden, Jeffrey Greenfield
Yujie Huang, … , David Lyden, Jeffrey Greenfield
Published April 10, 2017
Citation Information: J Clin Invest. 2017;127(5):1826-1838. https://doi.org/10.1172/JCI86443.
View: Text | PDF
Research Article Angiogenesis Oncology Article has an altmetric score of 39

A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma

  • Text
  • PDF
Abstract

Tumors are capable of coopting hematopoietic cells to create a suitable microenvironment to support malignant growth. Here, we have demonstrated that upregulation of kinase insert domain receptor (KDR), also known as VEGFR2, in a myeloid cell sublineage is necessary for malignant progression of gliomas in transgenic murine models and is associated with high-grade tumors in patients. KDR expression increased in myeloid cells as myeloid-derived suppressor cells (MDSCs) accumulated, which was associated with the transformation and progression of low-grade fibrillary astrocytoma to high-grade anaplastic gliomas. KDR deficiency in murine BM-derived cells (BMDCs) suppressed the differentiation of myeloid lineages and reduced granulocytic/monocytic populations. The depletion of myeloid-derived KDR compromised its proangiogenic function, which inhibited the angiogenic switch necessary for malignant progression of low-grade to high-grade tumors. We also identified inhibitor of DNA binding protein 2 (ID2) as a key upstream regulator of KDR activation during myeloid differentiation. Deficiency of ID2 in BMDCs led to downregulation of KDR, suppression of proangiogenic myeloid cells, and prevention of low-grade to high-grade transition. Tumor-secreted TGF-β and granulocyte-macrophage CSF (GM-CSF) enhanced the KDR/ID2 signaling axis in BMDCs. Our results suggest that modulation of KDR/ID2 signaling may restrict tumor-associated myeloid cells and could potentially be a therapeutic strategy for preventing transformation of premalignant gliomas.

Authors

Yujie Huang, Prajwal Rajappa, Wenhuo Hu, Caitlin Hoffman, Babacar Cisse, Joon-Hyung Kim, Emilie Gorge, Rachel Yanowitch, William Cope, Emma Vartanian, Raymond Xu, Tuo Zhang, David Pisapia, Jenny Xiang, Jason Huse, Irina Matei, Hector Peinado, Jacqueline Bromberg, Eric Holland, Bi-sen Ding, Shahin Rafii, David Lyden, Jeffrey Greenfield

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 Total
Citations: 1 3 1 3 5 3 2 5 1 24
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (24)

Title and authors Publication Year
Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer
Berg SZ, Berg J
Frontiers in Immunology 2025
SorLA restricts TNFα release from microglia to shape a glioma-supportive brain microenvironment.
Kaminska P, Ovesen PL, Jakiel M, Obrebski T, Schmidt V, Draminski M, Bilska AG, Bieniek M, Anink J, Paterczyk B, Jensen AMG, Piatek S, Andersen OM, Aronica E, Willnow TE, Kaminska B, Dabrowski MJ, Malik AR
EMBO reports 2024
Glioblastoma microenvironment—from biology to therapy
Read RD, Tapp ZM, Rajappa P, Hambardzumyan D
Genes & development 2024
ID2-ETS2 axis regulates the transcriptional acquisition of pro-tumoral microglia phenotype in glioma
Vázquez-Cabrera G, Škandík M, Roncier N, Real Oualit F, Cruz De Los Santos M, Baleviciute A, Cheray M, Joseph B
Cell Death and Disease 2024
Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort
She L, Gong X, Su L, Liu C
Frontiers in neurology 2023
Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors
P Rajappa, K Eng, R Bareja, E Bander, M Yuan, A Dua, U Maachani, M Snuderl, H Pan, T Zhang, U Tosi, I Ivasyk, M Souweidane, O Elemento, A Sboner, J Greenfield, D Pisapia
2022
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang Y, Brekken RA
Journal of leukocyte biology 2022
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study
She L, Gong X, Su L, Liu C
The oncologist 2022
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
Yuqing Zhang, Huocong Huang, Morgan Coleman, Arturas Ziemys, Purva Gopal, Syed M. Kazmi, Rolf A. Brekken
JCI Insight 2021
Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors
R Qiu, Y Zhong, Q Li, Y Li, H Fan
Frontiers in Cell and Developmental Biology 2021
Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics
Z Ye, X Ai, L Zhao, F Fei, P Wang, S Zhou
Oncogene 2021
Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
X Li, J Zhong, X Deng, X Guo, Y Lu, J Lin, X Huang, C Wang
Frontiers in immunology 2021
Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
L She, L Su, L Shen, C Liu
Frontiers in Oncology 2021
Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
A Hou, K Hou, Q Huang, Y Lei, W Chen
Frontiers in immunology 2020
Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target
R Gargini, B Segura-Collar, P Sánchez-Gómez
Cancers 2020
High expression of stromal signatures correlated with macrophage infiltration, angiogenesis and poor prognosis in glioma microenvironment
Y Tian, Y Ke, Y Ma
PeerJ 2020
The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models
G Gravina, A Mancini, A Colapietro, SD Monache, R Sferra, F Vitale, L Cristiano, S Martellucci, F Marampon, V Mattei, F Beirinckx, P Pujuguet, L Saniere, G Lorenzon, E van der Aar, C Festuccia
Cancers 2019
Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors
AS Ding, D Routkevitch, C Jackson, M Lim
Frontiers in immunology 2019
Delineating Pro-Angiogenic Myeloid Cells in Cancer Therapy
B Johnson, B Achyut, S Fulzele, A Mondal, R Kolhe, A Arbab
International journal of molecular sciences 2018
Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?
M Jaber, C Ewelt, J Wölfer, B Brokinkel, C Thomas, M Hasselblatt, O Grauer, W Stummer
Neurosurgery 2018
Cancer subtype identification using somatic mutation data
ML Kuijjer, JN Paulson, P Salzman, W Ding, J Quackenbush
British Journal of Cancer 2018
Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)
SS Oladipupo, AU Kabir, C Smith, K Choi, DM Ornitz
Scientific Reports 2018
Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
C Wang, M Jiang, H Hou, Q Lin, Z Yan, X Zhang
Oncology Letters 2018
New Chimeric Antigen Receptor Design for Solid Tumors
Y Wang, F Luo, J Yang, C Zhao, Y Chu
Frontiers in immunology 2017

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 5 news outlets
Posted by 9 X users
42 readers on Mendeley
See more details